TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
TScan Therapeutics has dosed the first patient in the pivotal Phase 3 ALLOHA-2 trial evaluating TSC-101 for the prevention of relapse in AML and MDS patients following stem cell transplantation. The trial utilizes a genetic randomization design based on HLA A*02:01 status, with relapse-free survival serving as the primary endpoint.
Key figures
- Drug Name
- TSC-101
- Phase Of Trial
- Phase 3
- Trial id
- NCT07702578
- Primary endpoint
- relapse-free survival
- Secondary endpoints
- ["overall survival","event-free survival"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.